INNOGEN-B (02591.HK): USD 1bn Efsubaglutide Alfa Licence Deal

On 19 November 2026, INNOGEN-B (02591.HK) licensed Efsubaglutide Alfa to Arcera for 15 years in Africa and other regions, with up to USD 38 million upfront.

NewTimeSpace News: On 19 November 2026, Guangzhou Innogen Pharmaceutical Group Co., Ltd. (stock code: 02591) announced that Hong Kong Innogen Pharmaceutical Holdings Company Limited, an indirect wholly-owned subsidiary acting as licensor, entered into a licence agreement on the same day with Arcera Life Sciences LTD, granting an exclusive licence for an initial term of 15 years to develop, solely to the extent necessary to obtain and maintain regulatory approvals, and commercialise the pharmaceutical product containing Efsubaglutide Alfa for human therapeutic use in selected countries in Africa, Latin America, the Middle East and Eastern Europe.

Hong Kong Innogen is entitled to upfront and near-term milestone payments of up to USD 38 million, including a non-refundable upfront payment of USD 15 million, as well as sales milestone payments and tiered royalties at rates of up to double-digit percentage based on aggregate annual net sales of the product in the territory. The total potential deal value is over USD 1 billion, the announcement said.

Arcera is a member of Arcera Life Sciences, a global pharmaceutical group. The Company said the licence leverages Arcera's established commercial network across emerging markets to accelerate the international expansion and commercial value of Efsubaglutide Alfa.

The licence agreement and the transactions contemplated thereunder are of a revenue nature in the ordinary and usual course of business and do not constitute any notifiable or connected transaction, the announcement said.

×
Share to WeChat

Open WeChat, use the "Scan", and share to my Moments.